XPHOZAH (tenapanor)
Control of serum phosphorus in chronic kidney disease on dialysis
ApprovedCommercial
Key Facts
Indication
Control of serum phosphorus in chronic kidney disease on dialysis
Phase
Approved
Status
Commercial
Company
About Ardelyx
Ardelyx is a mission-driven biotech focused on discovering, developing, and commercializing first-in-class, gut-targeted medicines for significant unmet needs in cardiorenal and metabolic diseases. The company has successfully transitioned to a commercial entity with two approved products derived from its core NHE3 inhibition platform, XPHOZAH® and IBSRELA®, and maintains a broad pipeline of 27 candidates. Its strategy leverages a unique mechanism of action to avoid systemic side effects, supported by strategic ex-U.S. partnerships and a dedicated commercial effort to capture value in large, underserved markets.
View full company profile